Gluten ID Test for Celiac Disease Risk

GLUTEN ID® is a celiac genetics health risk screening test designed for individuals, families, and populations. GLUTEN ID is developed and optimized by ResearchDx scientists and performed by Next-Generation sequencing (NGS) for detection of variants in the HLA-DQA1, DQB1 genes linked to celiac genetic risk haplotypes.

All celiac genetic risk DQ2, DQ8 haplotypes supported by Level I (the highest) Level of Evidence (LOE) are covered by the test. If none of the celiac risk-associated GLUTEN ID haplotypes are detected the result is reported as non-celiac genetics which has greater than 99% negative predictive value (NPV) for the development of celiac disease.

Cheek swab samples for GLUTEN ID can be collected non-invasively at home or in a physician’s office with results reported within 14 days.

For more information about ordering this test, visit:  targeted-genomics.com

Methodology: Next-Generation Sequencing (NGS) is used to assess the presence or absence of HLA-DQ2/DQ8 genes in individuals exhibiting symptoms associated with celiac disease. Genotypically, these genes are present in nearly 100% of celiacs. A negative test result may ‘rule-out’ celiac disease whereas a positive result should be followed with additional diagnostic testing to confirm a celiac disease diagnosis. Results should be interpreted in the context of the patient’s clinical and laboratory findings.

Contact us today to learn more about our extensive array of clinical, esoteric, and consulting laboratory services for biopharmaceutical and clinical diagnostics laboratories. Or visit our companion diagnostics company, ResearchDx, to learn how our IVD and biopharma development services can simplify delivery of your FDA-approved companion diagnostics on time.